I-Mab(US:IMAB) Jin Rong Jie·2025-08-20 13:50Core Insights - Tianjing Bio (IMAB) opened with a 10.2% increase, reaching $4.64 per share, with a total market capitalization of $534 million [1] - The company reported total revenue of 27.644 million RMB for the year ending December 31, 2023, representing a year-on-year growth of 112.48% [1] - The net profit attributable to the parent company was -1.466 billion RMB, showing a year-on-year increase of 41.54% [1] Financial Performance - Revenue for 2023 was 27.644 million RMB, up 112.48% compared to the previous year [1] - The net profit attributable to the parent company was -1.466 billion RMB, an increase of 41.54% year-on-year [1] Upcoming Events - Tianjing Bio is scheduled to disclose its fiscal year 2024 mid-term report on August 28, 2023, before the market opens in the Eastern US [1] Company Overview - Tianjing Bio is an offshore holding company that operates through its domestic subsidiary, focusing on innovative biopharmaceuticals in the fields of tumor immunity and autoimmune diseases [1] - The company's mission is to develop groundbreaking innovative biopharmaceuticals to address unmet clinical needs and improve the quality of life for patients globally [1] - Tianjing Bio aims to establish itself as a leading biopharmaceutical company rooted in China and oriented towards global markets [1]